New combo aims to shrink tumors in Hard-to-Treat breast cancer
Disease control
Recruiting now
This study tests whether a new drug called tinengotinib, given with or without fulvestrant, can shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2-). About 94 participants will receive the treatment to find the best dose and see if the combination wor…
Phase: PHASE2 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC